SecBot SecBot
8-K ·Filed Jun 26, 2026

SYK

STRYKER CORP
NEUTRAL
Impact 2/10
Horizonweeks Processed4mo ago SEC0000310764-26-000041
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This filing is purely administrative, a segment recast with no new financial information or corporate events. There is no trading signal. Monitor the next quarterly report for organic growth trends in the new Ortho Tech business and any impact on segment margin trajectory.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$332.71
T+0 close · Jun 26, 2026 · via day close
Latest settled
−17.59%
T+60 · $274.19
Vs SPY
−22.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 26 $332.71entry
  2. T+1 · 5mo ago −0.66%α −2.31% · $330.52
  3. T+5 · 5mo ago −1.85%α −4.02% · $326.54
  4. T+20 · 4mo ago −4.13%α −5.39% · $318.97
  5. T+60 · 8w ago −17.59%α −22.07% · $274.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stryker filed an 8-K to recast historical segment financials for 2023-2025 following a Q1 2026 organizational restructuring that created a new Ortho Tech business (combining orthopaedic instruments with Mako/enabling technologies). This is a routine accounting change to conform prior-period segment data to the new reporting structure, it does not restate or amend the audited consolidated financial statements and contains no new financial results, guidance, or material events.

Key Facts

  • Stryker reorganized in Q1 2026, creating a new Ortho Tech business within the Orthopaedics segment by combining orthopaedic instruments from Instruments with Mako and enabling technologies from Other Orthopaedics.
  • The two reportable segments remain MedSurg and Neurotechnology and Orthopaedics.
  • Historical segment financials for 2023-2025 have been recast to reflect the new structure; consolidated results are unchanged.
  • The filing includes recast MD&A, financial statements, and notes from the 2025 10-K, plus an auditor consent (Exhibit 23.1).
  • The recast does not amend or restate previously issued audited financial statements.

Financial Impact

No new financial data; recast of existing segment-level sales and operating income only. Consolidated net sales for 2025 were $25,116 million, net earnings $3,246 million, and diluted EPS $8.40, all unchanged from the original filing.

segment net salessegment operating income

Risk Factors

  • None directly from this filing; the reorganization may cause temporary noise in segment-level comparisons until the new structure stabilizes.

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
77% bullish (35 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000310764-26-000041
Exhibit: ex231-consentofindependent.htm0000310764-26-000041
Document: syk-20260626.htm0000310764-26-000041
Document: 0000310764-26-000041-index-headers.html0000310764-26-000041
Document: 0000310764-26-000041-index.html0000310764-26-000041
Document: 0000310764-26-000041.txt0000310764-26-000041

Track record

29 reports on SYK

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
  2. Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
  3. Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
  4. Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
  5. Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
  6. Oct 29, 202619d ago 8-K Bearish 6/10 No price data
  7. Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
  8. Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
  9. Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
  10. Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Thu (12h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026